Clinical Trial

A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated June 16, 2022 (before its estimated July 15, 2024 completion). Its status may not reflect the trial's current state.
Summary
To assess the efficacy and safety of Almonertinib versus placebo following chemoradiation in patients with stage III unresectable epidermal growth factor receptor mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2021-06-30.
Status change: Not Yet Recruiting → Recruiting 2022-06-13
Trial Details
NCT Number NCT04951635
Lead Sponsor Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions Non-small Cell Lung Cancer
Enrollment 150 participants
Start Date 2021-03-18
Primary Completion 2024-07-15 (estimated)
Study Completion 2027-01-15 (estimated)
Updated on ClinicalTrials.gov 2022-06-16